News from Polaris Group A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

08 Nov, 2016, 13:30 ET ADI-PEG 20 Radio-sensitizes Pancreatic Cancer Cells by Amplifying Early Endoplasmic Reticulum Stress

Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, can selectively enhance the effect of...


24 Oct, 2016, 14:31 ET ADI-PEG 20 Can Boost Anti-Tumor Immune Surveillance

Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, can boost anti-tumor immune surveillance...


06 Jun, 2016, 12:00 ET FLT-PET Scan Provides Early Evidence of Response to Arginine Depletion by ADI-PEG 20 in Argininosuccinate Synthetase Deficient Thoracic Tumors

 Polaris Group announced today that FLT-PET scan provided early evidence of response to arginine depletion by its lead therapeutic ADI-PEG 20...


06 Jun, 2016, 12:00 ET Polaris Group Reports Phase III Study Results of ADI-PEG 20 plus Best Supportive Care in Advanced Hepatocellular Carcinoma

 Polaris Group announced today that the phase III study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive...


03 Jun, 2016, 10:00 ET ADI-PEG 20 plus Gemcitabine and nab-Paclitaxel Shows Robust Anti-tumor Activity in Advanced Pancreatic Cancer

Polaris Group announced today results from an ongoing phase 1b study conducted at Memorial Sloan Kettering Cancer Center that tests combining...


11 Nov, 2015, 13:30 ET Polaris Group's ADI-PEG 20 Shows Robust Clinical Activity in Malignant Plural Mesothelioma and NSCLC When Combined with Standard First Line Chemotherapy Regimen

Polaris Group announced today the preliminary results from an ongoing phase 1 study that tests combining its lead therapeutic ADI-PEG 20 (pegylated...


03 Feb, 2015, 13:15 ET Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus FOLFOX in Advanced Gastrointestinal Malignancies

Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with folinic acid...


18 Dec, 2014, 13:30 ET Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation in the United States and the European Union for the Treatment of Malignant Pleural Mesothelioma

 Polaris Group announced today that its lead product candidate ADI-PEG 20 (pegylated arginine deiminase) has received orphan drug designation...


10 Dec, 2014, 13:30 ET Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 Plus Sorafenib in Advanced Hepatocellular Carcinoma

Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with sorafenib, a current...


03 Dec, 2014, 13:30 ET Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer

 Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with...


01 Dec, 2014, 13:30 ET Data Published by Researchers from Leading Cancer Institutes Show Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Causes Tumor Cytotoxicity through Previously Unidentified Mechanism

 Polaris Group announced today that data from a recent publication in the Proceedings of the National Academy of Sciences of the USA (PNAS)...


20 Nov, 2014, 13:30 ET Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma

Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with pemetrexed and cisplatin...


18 Nov, 2014, 13:30 ET Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Doxorubicin in HER2 Negative Breast Cancer

Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with doxorubicin for the...


27 Jan, 2014, 10:30 ET Polaris Group's ADI-PEG 20 is a Radiosensitizer of Pancreatic Cancer

Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, acts as a radiosensitizer of pancreatic...


02 Dec, 2013, 10:30 ET Polaris Group Files New IND for ADI-PEG 20 in Leukemia

 Polaris Group announced today that it has filed an Investigational New Drug Application (IND) application with the United States Food and Drug...


06 Nov, 2013, 15:00 ET Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia

 Polaris Group announced today that the first patient has been dosed in its Phase 2 trial of ADI-PEG 20, arginine deiminase formulated...


28 Oct, 2013, 07:00 ET Polaris Group Announces Positive Results for Phase 2 Study of ADI-PEG 20 in Malignant Pleural Mesothelioma

Polaris Group announced today that positive results from a randomized Phase 2 trial of ADI-PEG 20, arginine deiminase formulated with...


22 Oct, 2013, 10:00 ET Polaris Group Files New IND for ADI-PEG 20 in Breast Cancer

 Polaris Group announced today that it has filed an Investigational New Drug Application (IND) application with the United States Food and Drug...


17 Apr, 2013, 10:00 ET Metabolic Changes Induced by Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Are Associated with Anticancer Activity in Bladder Cancer and Mesothelioma Models Especially Those That Are Deficient in Key Metabolic Protein

 Scientists from academic institutions reported at the 2013 annual American Association for Cancer Research meeting, results from preclinical...


12 Jun, 2012, 09:00 ET Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma

 Scientists from numerous institutions reported at the 2012 annual American Association for Cancer Research meeting, results from preclinical...


29 Feb, 2012, 10:29 ET Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Pediatric Patients with Emphasis on Leukemia, Lymphoma and Sarcoma

 Polaris Group (Polaris) today announced that it has dosed the first patient in a Phase 1 clinical trial evaluating its lead cancer...


10 Jan, 2012, 09:00 ET Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Combination with Docetaxel in Advanced Solid Tumors with Emphasis on Prostate Cancer

SAN DIEGO, Jan. 10, 2012 /PRNewswire/ -- Polaris Group (Polaris) today announced that it has dosed the first patient in a Phase 1...


28 Jul, 2011, 08:00 ET Polaris Group Doses First Patient in Pivotal Phase 3 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 for the Treatment of Hepatocellular Carcinoma

Polaris Group (Polaris) today announced that it has dosed the first patient in a pivotal Phase 3 clinical trial evaluating its lead cancer...


18 May, 2011, 08:00 ET Ludwig Institute for Cancer Research and Polaris Group Form Collaboration to Expand Development of Polaris' Novel Cancer Drug, ADI-PEG 20

Ludwig Institute for Cancer Research LTD (LICR) and Polaris Group (Polaris) today announced the formation of a collaboration to expand development...